Core Viewpoint - The company, Maiwei Biotech, is facing significant financial challenges, having accumulated losses exceeding 30 billion yuan since its IPO in 2022, and is now seeking to raise funds through various financing methods to maintain operations and manage its debt levels [1][2][3]. Financing and Debt Management - Maiwei Biotech plans to apply for the issuance of targeted debt financing tools not exceeding 5 billion yuan to optimize its debt structure and reduce financial costs [1]. - The company has increased its credit and financing limits from an initial 2.3 billion yuan to 6.2 billion yuan in 2024 [1][3]. - As of the end of 2024, the company's debt-to-asset ratio has surged to 63.61%, with net cash flow from operating activities reported at -9.56 billion yuan [3]. Financial Performance - The company reported net losses of 9.55 billion yuan, 10.53 billion yuan, and 10.44 billion yuan for the years 2022 to 2024, totaling over 30 billion yuan in losses [2][3]. - Cumulative R&D expenses from 2022 to 2024 approached 24 billion yuan, indicating a heavy investment in new drug development [2]. Product Pipeline and R&D Challenges - Maiwei Biotech has 16 core products in various stages of development, with only 3 approved for market release [1][2]. - The company has faced personnel turnover, including the departure of key figures such as Zhang Jinchao, who was instrumental in the development of antibody drugs [4][5]. Corporate Structure and Strategy - The company has expanded its operations through multiple acquisitions, spending 366 million yuan to acquire five companies since 2018, which has led to a complex corporate structure with 18 subsidiaries [6][7]. - Despite the extensive network of subsidiaries, only three are currently profitable, raising concerns about the sustainability of the business model [7]. Industry Context - The biotech industry is characterized by high R&D costs and long development timelines, with an average cost exceeding 1 billion USD and a development period of over 10 years for new drugs [3]. - Analysts suggest that the company's early investment in production capabilities may be premature given its current stage of development, leading to questions about its strategic direction [8].

迈威生物表示，公司营运资金主要依赖于外部融资，若经营发展所需开支超过可获得的外部融资，将造 成公司经营活动现金流紧张，进而对公司的产品研发投入、人才引进、团队稳定等方面造成不利的影 响。 3月30日，迈威生物发布2024年年度报告，公司实现营业收入2亿元，同比增长56.28%；归属于上市公 司股东的净利润为-10.44亿元。自2022年在科创板上市以来，迈威生物已累计亏损超30亿元。持续亏 损、资产负债率不断攀升的迈威生物，同日还宣布，拟向中国银行间市场交易商协会申请注册发行规模 不超过5亿元的定向债务融资工具。 三年累计亏损超30亿元 2024年，迈威生物营业收入大增主要得益于药品销售收入的显著增长，其中，地舒单抗的上市对收入增 长贡献突出。迈威生物2024年实现药品销售收入1.45亿元，同比增长243.53%，其中，地舒单抗药品销 售收入为1.40亿元，同比增长230.17%。 2024年迈威生物亏损10.44亿元，同比减亏0.90%，尽管亏损有所缩窄，但亏损减少幅度远不及营收增 幅。对于亏损，迈威生物表示，主要系随着公司投入大量资金用于新药研发管线持续推进，多个创新药 物处于关键试验研究阶段，整体研发投 ...

据查阅，迈威生物是一家全产业链布局的创新型生物制药公司，专注于肿瘤和年龄相关疾病，涉及肿 瘤、自身免疫、骨疾病、眼科、血液、感染等治疗领域。公司于2022年1月在上海证券交易所科创板上 市，募集资金净额为33.03亿元。 薪酬方面，2024年，迈威生物副总经理HAIWU（武海）薪酬368.67万元，位列董监高首位，另有5名在 任董监高薪酬超200万元，分别为首席科学家、迈威（美国）总裁杜欣薪酬280.5万元，副总经理、财务 负责人华俊薪酬277.71万元，董事长、总经理刘大涛薪酬270.5万元，副总经理、董事会秘书胡会国薪酬 为219.38万元，副总经理陈曦薪酬为210.19万元。 | | | | | | | | | | | 报告期内 | alle Level The | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 明多 | 性别 | 年齡 | 任期起始 日期 | 任期终止 目期 | 年初持胶数 | 年末特股数 | 年度内股份 增减变动量 | 增减变动 图图 | 从公司装 得的税前 报酬总额 ...

Core Viewpoint - The company plans to expand its business scope to include medical research, drug production, and related activities, requiring amendments to its articles of association and subsequent registration with the industrial and commercial authorities [1][2]. Summary by Relevant Sections Business Scope Changes - The company intends to add medical research and experimental development, drug production, and other related activities to its existing business scope [1]. - The revised business scope includes general projects such as technical services, technology development, medical research, gene diagnosis and treatment technology development, and various medical device rentals [1][2]. Articles of Association Amendments - The amendments to the articles of association will reflect the new business scope and will require approval from the company's shareholders [1]. - Other contents of the articles of association will remain unchanged, and the final approved content will be based on the registration authority's confirmation [2]. Shareholder Meeting - The board of directors will seek authorization from the shareholder meeting to allow management and authorized representatives to handle the necessary registration and filing related to the business scope changes [2].

Meeting Overview - The second session of the Supervisory Board of Maiwei (Shanghai) Biotechnology Co., Ltd. was held on March 30, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1]. Resolutions Passed - The Supervisory Board approved the 2024 Annual Report and its summary, affirming that the report accurately reflects the company's financial status and operational results without any misleading statements or omissions [2]. - The 2025 Financial Budget Report was also approved, pending review at the 2024 Annual General Meeting [2]. - The 2024 Financial Settlement Report received approval, also subject to the upcoming shareholder meeting [2]. - A special report on the storage and actual use of funds raised in 2024 was approved, confirming compliance with relevant regulations and proper use of funds [2][3]. - The 2024 Internal Control Evaluation Report was approved, indicating effective internal control execution without significant defects [3]. - The profit distribution plan for 2024 was approved, pending shareholder review [4]. - The reappointment of Ernst & Young Hua Ming as the auditing firm for 2025 was approved, ensuring compliance with legal and regulatory requirements [4]. - The 2025 Employee Compensation Plan was approved, aimed at enhancing management levels and motivating employees [5]. - The proposal for the company and its subsidiaries to apply for credit limits from financial institutions was approved, aligning with business needs [5][6]. - The proposal for the use of surplus funds from completed fundraising projects to supplement working capital was approved, enhancing fund utilization efficiency [6][7].

Group 1 - The company, Mabwell (Shanghai) Biotechnology Co., Ltd., is convening its 2024 Annual General Meeting on April 21, 2025, at 15:00 in Shanghai [1][3] - Voting will be conducted through a combination of on-site and online methods, utilizing the Shanghai Stock Exchange's network voting system [1][4] - The registration date for shareholders to attend the meeting is April 14, 2025, and shareholders must complete registration by April 15, 2025, at 17:00 [5][6] Group 2 - The agenda includes several non-cumulative voting proposals, such as the application for credit limits from financial institutions and the approval of the 2024 annual report [2][9] - The meeting will also hear reports from independent directors regarding their performance for the year 2024 [2][3] - Shareholders can delegate their voting rights to representatives, who do not need to be shareholders themselves [5][8]

Core Viewpoint - The company aims to enhance operational efficiency and shareholder returns through its "Quality Improvement and Efficiency Enhancement Action Plan" for 2025, focusing on innovative drug development and global market expansion [1][18]. Group 1: Drug Development and Pipeline - The company is concentrating on the research and development of innovative drugs, with a pipeline of 16 core products, including 12 innovative drugs and 4 biosimilars, primarily targeting oncology and age-related diseases [1]. - The key pipeline product 9MW2821 is an innovative antibody-drug conjugate (ADC) targeting Nectin-4, with clinical trials ongoing for multiple cancers, including bladder, cervical, esophageal, and triple-negative breast cancer [2]. - The company has received several FDA designations for 9MW2821, including Fast Track Designation (FTD) and Orphan Drug Designation (ODD) for various cancer treatments [3]. Group 2: Clinical Trials and Research - The company has reported significant clinical trial progress, with over 800 participants enrolled in various studies for 9MW2821, demonstrating promising efficacy and safety data [2][4]. - The company is also advancing other innovative pipelines, such as 9MW1911 for chronic obstructive pulmonary disease (COPD), which has shown good safety and tolerability in early trials [5][6]. Group 3: Commercialization and Revenue Growth - The company has achieved a 56.28% year-on-year increase in revenue for 2024, primarily driven by a 243.53% increase in drug sales, amounting to 144.59 million yuan [7]. - The company has successfully launched three products, with significant sales and hospital access achieved for its innovative drugs [7][8]. Group 4: Global Market Expansion - The company is actively pursuing international collaborations and market expansion, having established agreements for the commercialization of its products in multiple countries, including India, Brazil, and Peru [9][10]. - The company aims to leverage its innovative drug pipeline and international partnerships to enhance its global market presence [10]. Group 5: Production and Supply Chain - The company has established production facilities compliant with international standards, enabling the manufacturing of antibodies and recombinant proteins for clinical and commercial use [11][12]. - Ongoing projects aim to expand production capacity and improve efficiency, supporting the company's growth and commercialization efforts [13][14]. Group 6: Corporate Governance and Investor Relations - The company is enhancing its corporate governance structure to align with international standards, ensuring compliance and transparency for investors [15][18]. - The company is committed to improving information disclosure and investor communication, establishing multiple channels for engagement [16][18]. Group 7: Management and Incentives - The company has implemented a performance-based incentive system for management, promoting alignment between management and shareholder interests [17]. - The company is focused on talent development and retention, fostering a culture of innovation and growth [17].

Group 1 - The company has three independent directors: Qin Zhengyu, Xu Qing, and Zhao Qian, who have conducted a self-assessment of their independence [1] - The self-assessment results indicate that all independent directors meet the independence requirements as per the relevant regulations, with no direct or indirect interests that could affect their objective judgment [1] - The board confirmed that the independent directors have not held any positions other than their role as independent directors and have no conflicts of interest with the company or its major shareholders [1] Group 2 - The independent directors have maintained a high level of independence throughout the reporting period, fulfilling their duties in accordance with the strict regulations and requirements of the relevant governance guidelines [1] - The independent directors have provided fair and independent professional opinions to support the company's decision-making processes [1]

Company Overview - Mabwell Biotech (688062.SH) is an innovative biopharmaceutical company with a full industry chain layout, committed to transforming innovation from dreams into reality and exploring life to benefit health [1] - Since its establishment in 2017, the company has built an innovative system covering the entire drug development cycle, from antibody drug target validation and molecular discovery to commercialization [1] - The company has a competitive pipeline with 16 products in various stages, including 12 innovative drugs and 4 biosimilars, focusing on oncology and age-related diseases [1] Production and Compliance - Mabwell has established a production base in Taizhou, Jiangsu, compliant with NMPA, FDA, and EMA GMP standards, and is constructing large-scale commercial production bases in Shanghai and Taizhou [2] - The company aims to become a leading international innovative biopharmaceutical company with a full industry chain layout [2] Key Performance Indicators - As of the end of the reporting period, the company has three marketed products: Junmai Kang®, Mai Li Shu®, and Mai Wei Jian® [4] - Mai Li Shu® was approved for marketing in March 2023, with 245,341 units shipped and 1,137 new hospitals added during the reporting period [4] - Mai Wei Jian® was approved in March 2024, with 12,530 units shipped and 75 hospitals added [4] Financial Data - The report includes financial data in RMB, with discrepancies noted against the annual financial report [3] - The company has achieved significant milestones in product commercialization and pipeline development, including the approval of biosimilars and innovative drugs [5][6] Research and Development - Mabwell focuses on unmet clinical needs, developing biosimilars and innovative drugs targeting mature targets, with a complete industrial chain from preclinical research to commercialization [22] - The company has made progress in various clinical trials, including the development of 9MW2821, a targeted Nectin-4 ADC for esophageal cancer, and 9MW0813, a biosimilar for diabetic macular edema [24][25] Governance and ESG - The company has established a governance structure in compliance with relevant laws and regulations, including a board of directors and various committees [8] - Mabwell actively promotes ESG principles, integrating them into its governance framework to ensure sustainable development and compliance [10][11] Intellectual Property and Information Security - The company has filed 79 new patent applications and received 8 new patent grants during the reporting period, with a total of 466 patent applications filed [20] - Mabwell emphasizes information security and data protection, adhering to relevant laws and establishing comprehensive management systems [21][22]

证券代码：688062 证券简称：迈威生物 公告编号：2025-013 迈威（上海）生物科技股份有限公司 关于部分募集资金投资项目结项 并将节余募集资金永久补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迈威（上海）生物科技股份有限公司（以下简称"迈威生物"或"公司"） 于 2025 年 3 月 30 日分别召开第二届董事会第十七次会议、第二届监事会第十六 次会议及第二届董事会独立董事专门会议第三次会议，审议通过了《关于部分募 集资金投资项目结项并将节余募集资金永久补充流动资金的议案》，同意公司将 首次公开发行股票募集资金投资项目（以下简称"募投项目"）"年产 1,000kg 抗体产业化建设项目"予以结项，并将节余募集资金中的 18,944.20 万元用于永 久补充流动资金。公司监事会发表了明确同意的意见，保荐机构海通证券股份有 限公司亦对上述事项出具了明确同意的核查意见，该事项尚需提交公司股东大会 审议。现将相关情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会于 2021 年 12 月 ...